Lenvatinib 4mg capsules | Lenvatinib | Millionpharma

LENVATINIB 4MG

DESCRIPTION:

Lenvatinib 4mg is a multi-kinase inhibitor and antineoplastic agents. It is a type of targeted treatment which target the specific cancer cells and hence reduces side effects caused by affected cells.
Lenvatinib 4mg capsule inhibits the protein which promotes cell division by preventing the cancer cell development.

Thyroid cancer

PRESCRIBED FOR:

In adult,Lenvatinib 4mg is indicated for the treatment of metastatic, progressive, radioactive Differentiated Thyroid cancer.
Lenvatinib 4mg capsule in combination with everolimus is indicated in patients for the treatment of advance Renal Cell Carcinoma following treatment before anti-angiogenic therapy.
Lenvatinib 4mg is also indicated for the first line treatment in patients suffering with unresectable hepatocellular carcinoma.

MECHANISM OF ACTION:

Lenvatinib 4mg capsule is a tyrosine kinase inhibitor which has shown mainly anti-angiogenic properties, and direct prevention of malignant developed was also observed inside the models. Lenvatinib 4mg which selectively prevents the kinase functions of vascular endothelial growth factor receptors 1(FLT1), 2 (KDR), 3 (FLT4).
Although not been studied directly with Lenvatinib 4mg, the mechanism of action (MOA) for High blood pressure is hypothesizing to be resolve by the prevention of VEGFR2 in vascular endothelial cells.
Same as the, the action for proteinuria is hypothesizing to be interfere with down regulation of VEGFR1 and VEGFR2 in the cell of bowman’s capsules of the glomerulus.

LENVATINIB 4Mg

PRODUCT DETAILS:

Brand :Lenvatinib
Ingredients : Lenvatinib
Strength : 4mg
Manufactured : Eisai Co.Ltd.
Package : Pack of 20 Capsules.

ADME:

Absorption:

Time to high plasma concentration is 1-4 hours post dose. Effect with food is low to the extent Lenvatinib of absorption.
Distribution:
bounding of Human plasma proteins is 98% to 99%.
Metabolism:
Lenvatinib 4mg is primarily metabolized in CYP3A. Lenvatinib 4mg metabolic pathway is identified as enzymatic and non-enzymatic processes.
Elimination:
eliminated via 64% feces and 25% urine.

DOSAGEMANAGEMENT:

The usual dose of Lenvatinib 4mg capsule for the adult patients is 24mg and administer has two 10mg capsules and one 4mg capsule given orally, once daily taken with or without food.
The Lenvatinib 4mg should continue until disease progression or until unacceptable toxicity occurs.
Take Lenvatinib 4mg capsule at the same time.
Patients with severe renal or hepatic impairment the dose is 14mg administer once daily orally.

OVERDOSE:

Lenvatinib 4mg is not expected to be dialyzable because of maximum plasma protein binding and if the dose getting of Lenvatinib 4mg orally then causes death due to multiorgan dysfunction occurred in the patients.

PRECAUTIONS:

• Blood pressure may increase while treatment with Lenvatinib 4mg. Your doctor will preferably check your blood pressure during your treatment.
• Inform the doctor if you are allergic to Lenvatinib 4mg, any other regimens, or any of the ingredients in Lenvatinib 4mg capsule.
• Other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may to change the doses of your drugs or guide carefully for adverse reaction.
• Inform doctor if you have or had seizures, hypertension, a stroke, a heart attack, , especially those due to blood clots, a fistula, a tear in the wall of your GIT, QT interval prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death), low levels of Ca, K or Mg in your blood, bleeding problems, or cardiac, renal, or hepatic disease.
• Take into the knowledge that Lenvatinib 4mg may reduce the fertility in men and women. It not means that you or your partner cannot become pregnant. Inform doctor before if you are pregnant or plan to become pregnant. After becoming pregnant, you should use birth control while treatment with Lenvatinib 4mg and for at least 2 weeks after your treatment, become pregnant during Lenvatinib therapy, call your doctor immediately. Lenvatinib 4mg may harm the fetus.
• Inform the doctor if you are breastfeeding or plan to breastfeed. Avoid breastfeed during Lenvatinib 4mg treatment.

SIDE EFFECTS:

Common side effects:
Tiredness
Peeling of skin on palms and sole of the feet
Constipation
Loss of appetite
Weight loss
Joint and muscle pain
Insomnia.
Serious side effects :
Shortness of breath
Chest pain
Pain in arm, back, neck or jaw
Seizures
Black, tarry or bloody stools
Heavy menstrual bleeding
Coughing up blood
Yellowing of the skin or eyes.

DRUG INTERACTION:

Lenvatinib 4mgcombination with Carboplatin, paclitaxel has no specific pharmacokinetics impact
Interaction with CYP3A, Pglycoprotein (P-gp) inhibitors and inducers has no dose adjustment for Lenvatinib 4mg.

MISSED DOSE:

If patients missed to have the dose of drug and should be taken within the time and cannot be taken within 12 hours, otherwise the missed dose should be skipped and follow the next dosing schedule. Please consult with the doctor

PREGNANCY:

When administrated to pregnant, Lenvatinib 4mg drugs can cause harm to the fetal. There are no available human data related to drug associated risk. Advice pregnant women specific risk to fetus.

LACTATION:

Excretion in human milk is unknown. It’s not known that drug is present in human milk Because of the serious side effects in infants from the drug, Advice to avoid breast feeding during treatment with Lenvatinib 4mg.

STORAGE:

Store at 25°C
Keep out of the children hands Discard the after-expiry date Dispense the drug only in original container

CONTACT US:

 

PHONE NO:+91-9940472902

E-MAIL:millionhealthpharmaceuticals@gmail.com

WEBSITE URL:https://millionpharma.com/lenvatinib-4mg.php